Table 4. Therapy at baseline and month-12 visit.
Overall (n = 729) | HTN (n = 392) | DN (n = 116) | GN (n = 126) | TIN (n = 69) | PKD (n = 26) | P | |
---|---|---|---|---|---|---|---|
LSD (%) | |||||||
Baseline | 22.8 | 25.6 | 18.0 | 19.3 | 23.1 | 16.7 | 0.354 |
Month 12 | 26.2 | 26.4 | 31.5* | 19.3 | 29.2 | 25.0 | 0.301 |
BP lowering drugs (n) | |||||||
Baseline | 2.2±1.3 | 2.5±1.2 | 2.5±1.2 | 1.7 ±1.3 | 1.0±1.1 | 1.6±1.6 | <0.0001 |
Month 12 | 2.7±1.4* | 2.8±1.2* | 3.3±1.5* | 2.5±1.4* | 1.5±1.4* | 2.0±1.4* | <0.0001 |
RAS inhibitors (%) | |||||||
Baseline | 74.9 | 82.1 | 77.4 | 67.5 | 54.3 | 69.2 | <0.0001 |
Month 12 | 85.3* | 88.8* | 75.6 | 88.9* | 60.0* | 76.9 | <0.0001 |
B-blockers (%) | |||||||
Baseline | 27.4 | 33.9 | 30.4 | 16.7 | 5.8 | 24.0 | <0.0001 |
Month 12 | 36.7* | 41.1* | 46.1* | 27.8* | 14.5* | 32.0 | <0.0001 |
CCBs (%) | |||||||
Baseline | 34.9 | 39.0 | 48.7 | 20.6 | 17.4 | 28.0 | <0.0001 |
Month 12 | 43.9* | 48.7* | 60.9* | 26.2 | 24.6 | 32.0 | <0.0001 |
Furosemide (%) | |||||||
Baseline | 23.1 | 25.0 | 33.9 | 19.0 | 8.7 | 4.0 | <0.0001 |
Month 12 | 34.3* | 34.4* | 51.3* | 34.9* | 11.6 | 12.0 | <0.0001 |
ESA (%) | |||||||
Baseline | 3.0 | 2.6 | 0.9 | 5.6 | 4.3 | 3.8 | 0.256 |
Month 12 | 14.4* | 14.3* | 19.1* | 12.7* | 12.9* | 7.7 | 0.482 |
Iron supplement (%) | |||||||
Baseline | 4.1 | 4.3 | 3.5 | 1.6 | 8.7 | 4.0 | 0.210 |
Month 12 | 18.2* | 16.3* | 26.1* | 17.5* | 14.5 | 24.0 | 0.136 |
Statins (%) | |||||||
Baseline | 30.0 | 31.1 | 45.2 | 26.2 | 10.1 | 16.9 | <0.0001 |
Month 12 | 43.7* | 45.7* | 55.7* | 38.1* | 29.0* | 28.0 | 0.002 |
Vitamin D (%) | |||||||
Baseline | 4.0 | 3.1 | 0.9 | 7.1 | 8.7 | 4.0 | 0.026 |
Month 12 | 13.9* | 12.5* | 9.6* | 21.4* | 14.5 | 16.0 | 0.074 |
P binders (%) | |||||||
Baseline | 0.3 | 0.3 | 0 | 0.8 | 0 | 0 | 0.769 |
Month 12 | 2.1* | 1.3 | 4.3 | 0.8 | 4.3 | 4.0 | 0.115 |
Data are mean±SD or % of patients and (95%CI). RAS, renin-angiotensin system; BP, blood pressure; LSD, low salt diet (UNaV <100 mmol/24h); ESA, erythropoiesis stimulating agents.
* P<0.05 versus baseline